The Patient Journey in Diagnostic-Driven Therapies: Why Eligible Patients Are Being Missed

Diagnostic-driven therapies do not underperform because the science falls short. They underperform when the patient journey breaks down. Across real-world healthcare systems, identifying eligible patients is rarely straightforward.

Testing occurs across multiple laboratories and institutions. Results come in at different stages of care. Interpretation is then shared across clinicians, pathologists, and multidisciplinary teams. By the time eligibility is fully understood, treatment decisions are often already underway. This complexity makes early identification across the patient journey difficult to achieve.

The challenge is not a lack of data. It is the inability to see where opportunity exists while action can still make a difference. Unlocking the full potential of diagnostic-driven therapies depends on more than innovation alone. Is reliant on understanding where patients are progressing through the pathway. It also depends on clinical practice gaps, and where intervention can influence therapy uptake.

Visibility into the patient journey is the first step to therapy adoption

When diagnostic-driven therapies fail to meet full clinical or commercial potential, attention often turns to downstream factors. These include awareness, engagement, or prescribing behaviour.

But many of the most significant barriers occur much earlier in the patient journey.

Eligible patients may be identified too late. Diagnostic pathways may stall. Treatment opportunities may narrow before the appropriate intervention occurs. In complex healthcare systems, these gaps are rarely caused by a single failure point. They emerge across fragmented testing pathways. Or by disconnected workflows and delays between diagnostic insight and clinical action.

The result? Missed opportunities across the patient journey. And missed chances to influence treatment decisions while the pathway is still open.

For biopharma teams, this creates a fundamental commercialization challenge. Even the most innovative therapies struggle to reach full potential if eligibility isn't identified in time.

More data alone does not improve timing in the patient journey

Healthcare organizations have access to more data than ever before. From claims data and retrospective analytics, to market reporting and prescribing insights. It all helps explain the current state of the patient journey. But diagnostic-driven commercialization depends on something different. That is the ability to act while decisions are still forming.

Clinicians continuously interpret diagnostic results. They evaluate treatment pathways and determine the next step for each patient. Once the treatment decision window closes, opportunities to influence therapy become significantly fewer. This is why retrospective targeting is no longer enough.

Biopharma teams need decision-ready intelligence. Intelligence that's grounded in real-world diagnostic activity. This shows where opportunities exist while intervention is still possible.

By translating diagnostic and healthcare data into decision-ready intelligence, it becomes possible to:

• Identify where eligible patients are emerging
• Expose clinical practice gaps across the patient journey
• Understand which HCPs and labs are actively managing eligible patients
• Focus on what can still make a difference to therapy uptake

This shifts commercialization from retrospective reporting to prioritization driven by real diagnostic activity.

The treatment decision window defines outcomes across the patient journey

In diagnostic-driven therapies, timing is not a secondary consideration. It is central to adoption. Patient identification happens within a sequence of clinical and diagnostic decisions. This is what ultimately determines whether an eligible patient receives the right therapy.

When insight arrives early enough, clinicians have more opportunity to evaluate options with confidence. When visibility is too late, treatment pathways have already advanced. And this means opportunities for intervention narrow significantly.

This is why the treatment decision window matters. The value of intelligence is not simply in what it reveals, but when it becomes actionable.

From diagnostic intelligence to coordinated action

Visibility alone does not improve therapy uptake. Unlocking the full potential of diagnostic-driven therapies requires intelligence and engagement. This enables it to operate as a connected system - linking insight directly to timely action.

Our diagnostic and healthcare data comes from across an extensive, lab‑anchored data ecosystem. It is then transformed into decision-ready intelligence. From here, it reveals where patient opportunities exist, where pathways are slowing. And crucially, where intervention can still influence adoption.

That intelligence can then activate timely, targeted engagement within the treatment decision window. How? Through our Physician Engage platform. HCPs and laboratories shaping care can be identified within 24 hours of a diagnostic event. This enables engagement while treatment decisions are still forming. And that means the information is directly relevant to the patient in front of them.

This allows biopharma teams to:

• Rank resources based on real diagnostic activity
• Align engagement to active patient pathways
• Support HCP confidence in complex treatment decisions
• Intervene where practice gaps are limiting therapy adoption

The result is not broader outreach. It is coordinated action at the moment it matters most.

Closing practice gaps before the opportunity is lost

Unlocking the full potential of diagnostic-driven therapies does not begin after treatment decisions are made. It begins by understanding where the patient journey breaks. Eligible patients are at risk of being missed, and intervention can still change the outcome.

Decision-ready intelligence and timely engagement working in symphony drastically alter what happens next. Clinical practice gaps can be identified earlier. Intervention becomes more precise. And more eligible patients receive the therapies designed for them. That is how diagnostic intelligence becomes commercial action.

Meet Diaceutics at ASCO 2026

Meet us at ASCO 2026. Discover how decision-ready intelligence and timely patient identification can unlock the full potential of your diagnostic-driven therapy. Schedule a meeting here.